中国医院用药评价与分析2024，Vol.24Issue(4)：385-389,395,6.DOI:10.14009/j.issn.1672-2124.2024.04.001
广东省重组人凝血因子Ⅷ药物评价与遴选专家共识
Expert Consensus on Evaluation and Selection of Recombinant Human Coagulation Factor Ⅷ in Guangdong
摘要
Abstract
Recombinant human coagulation factor Ⅷ is the first-line treatment for hemophilia A recommended by authoritative guidelines.Various recombinant human coagulation factor Ⅷ have the same mechanism of action,which can temporarily replace the missing clotting factor Ⅷ that is needed for effective hemostasis in patients.There are differences in economy,pharmaceutical characteristics and other attributes.Therefore,pharmaceutical and clinical experts are organized by the Pharmacovigilance Professional Committee of Guangdong Pharmaceutical Association to formulate the Expert Consensus on Evaluation and Selection of Recombinant Human Coagulation Factor Ⅷ in Guangdong.Multi-dimensional evaluation on 6 kinds of recombinant human coagulation factor Ⅷ marketed in China are carried out from five aspects:pharmaceutical characteristics,efficacy,safety,economy and other attributes,so as to provide scientific basis for drug selection in medical institutions and promotes rational drug use in clinic.关键词
血友病A/重组人凝血因子Ⅷ/药物评价/遴选/专家共识Key words
Hemophilia A/Recombinant human coagulation factor Ⅷ/Drug evaluation/Selection/Expert consensus分类
医药卫生引用本文复制引用
广东省药学会药物警戒专业委员会,陈娟,郑萍..广东省重组人凝血因子Ⅷ药物评价与遴选专家共识[J].中国医院用药评价与分析,2024,24(4):385-389,395,6.基金项目
国家重点研发计划项目(No.2020YFC2005501) （No.2020YFC2005501）
